Breast Cancer

Shared insight on the monarchE trial, which studied adjuvant abemaciclib in patients with HR+, HER2- high-risk early breast cancer.

The European Commission approved pembrolizumab for use in combination with chemotherapy as neoadjuvant therapy, and then continued as monotherapy as adjuvant treatment after surgery for adults with locally advanced or early-stage triple-negative breast cancer at high risk of recurrence.

The prevalence of ESR1 mutations in endocrine-resistant metastatic breast cancer has paved an avenue for investigators to explore their role in the promotion of metastasis.

A significant improvement in progression-free survival has been reported with the oral selective estrogen receptor degrader elacestrant vs standard of care treatments for patients with estrogen receptor–positive, HER2-negative breast cancer.

Expert perspectives on the use of trastuzumab deruxtecan in a patient with HER2+ metastatic breast cancer.

Breast medical oncologist, Tiffany Traina, MD, shares a clinical scenario of a patient with HER2+ metastatic breast cancer and discusses her treatment approach in the neoadjuvant, adjuvant, and metastatic settings.

The combination of the TROP2-directed antibody-drug conjugate datopotamab deruxtecan and durvalumab showcased early activity with acceptable safety when used as first-line treatment in patients with locally advanced or metastatic triple-negative breast cancer, according to data from the phase 1b/2 BEGONIA trial.

Adam M. Brufsky, MD, PhD, emphasizes the importance of tyrosine kinase inhibitors in HER2-postive breast cancer and highlights the potential benefits of local salvage radiation therapy in patients with oligometastatic or de novo stage IV breast cancer.

Highlights from the OlympiA trial, which evaluated the use of olaparib in the adjuvant setting in patients with high-risk BRCA-mutated breast cancer.

Joyce O'Shaughnessy, MD, provides a brief overview of novel neoadjuvant and adjuvant treatment approaches being investigated in the setting of breast cancer.

Advancements in treatment options across the spectrum on women’s cancers include de-escalating therapy in HER2-positive breast cancer, using tisotumab vedotin-tftv in cervical cancer, shifting therapies to the frontline setting in endometrial cancer, and using checkpoint inhibitors in ovarian cancer.

Dr Pegram discusses approaches to treatment sequencing in HER2-positive metastatic breast cancer, the influence of the DESTINY-Breast03 trial (NCT03529110) on the breast cancer treatment paradigm, and ongoing research in the field.

Closing out her discussion on HER2+ metastatic breast cancer, Cynthia Lynch, MD, shares her excitement for treatment strategies in the setting of brain metastases.

Entrectinib produced deep and durable responses in patients with breast cancer harboring NTRK fusions.

Shared insight on specific treatment options in breast cancer made available when patients are found to have actionable targets via molecular testing.

Expert perspectives on platforms for molecular testing in breast cancer, as well as the actionable targets that treating physicians should be looking for.

Heidi Ko, DO, discusses unmet needs in patients with PD-L1–negative triple negative breast cancer.

The addition of abemaciclib to endocrine therapy improved invasive disease-free survival and distant relapse-free survival vs endocrine therapy alone in patients with high-risk, hormone receptor–positive, HER2-negative, early-stage breast cancer, irrespective of menopausal status.

The addition of nivolumab to trastuzumab deruxtecan did not result in a marked clinical benefit in patients with locally advanced unresectable or metastatic HER2-positive breast cancer.

Virginia G. Kaklamani, MD, discussed the emerging role of PARP inhibitors, practice-changing updates in HER2-positive breast cancer, the utilization of CDK4/6 inhibitors in hormone receptor–positive, HER2-negative breast cancer, and the various therapeutic classes and their effects on care in triple-negative breast cancer.

HER2 expression appeared to be a significant predictor for response to fam-trastuzumab deruxtecan-nxki, according to findings from a biomarker analysis of patients with metastatic breast cancer in the phase 2 DAISY trial.

The addition of adjuvant abemaciclib to endocrine therapy resulted in a clinically meaningful reduction in the risk of developing invasive disease, particularly incurable distant metastatic disease, in patients with high-risk, hormone receptor–positive, HER2-negative, early breast cancer who comprised cohort 1 of the phase 3 monarchE trial.

Nearly all patients with HER2-positive breast cancer with brain metastases who received fam-trastuzumab deruxtecan-nxki elicited benefit, according to data from a primary outcome analysis of the phase 2 TUXEDO-1 trial.

The combination of alpelisib plus endocrine therapy elicited a clinical benefit across all subgroups of patients with hormone receptor–positive, HER2-negative advanced breast cancer with PIK3CA mutations.

Heather McArthur, MD, MPH, discusses the FDA approval of fam-trastuzumab deruxtecan-nxki for second-line treatment in HER2-positive metastatic breast cancer.